PepGen
Develops peptide-enabled oligonucleotide therapies with a clinical focus on myotonic dystrophy type 1.
$3.08
After-hours close−0.00 (−0.16%)
At close$3.09(+0.49%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.27 | — | — |
| Aug 2026 | −$0.28 | −$0.26 | +8.6% |
| May 2026 | −$0.31 | −$0.26 | +16.1% |
| Mar 2026 | −$0.40 | −$0.27 | +32.5% |
| Nov 2025 | −$0.63 | −$0.52 | +17.5% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.27 | — | — | — | — | — |
| Aug 6, 2026 | −$0.28 | −$0.26 | +8.6% | — | — | — |
| May 12, 2026 | −$0.31 | −$0.26 | +16.1% | — | — | — |
| Mar 4, 2026 | −$0.40 | −$0.27 | +32.5% | — | — | — |
| Nov 12, 2025 | −$0.63 | −$0.52 | +17.5% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 24, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 6, 2024 | ||||||
| Nov 8, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 23, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 12, 2022 | ||||||
| May 9, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||